Department of Pathology and Laboratory Medicine, Advanced Medical Research Institute, Bhubaneswar, India.
Department of Pathology and Laboratory Medicine, CORE Diagnostics, Gurgaon, Haryana, India.
Mod Pathol. 2022 Mar;35(3):361-375. doi: 10.1038/s41379-021-00969-6. Epub 2021 Nov 20.
Low-grade oncocytic tumor (LOT) has been recently proposed as a unique renal tumor. However, we have encountered tumors with more oncocytoma-like morphology that show diffuse keratin 7 reactivity, which we sought to characterize molecularly. Eighteen tumors with a diffuse keratin 7 positive and KIT negative pattern were identified from 184 with predominantly oncocytoma-like histology. These tumors were subjected to detailed immunohistochemical evaluation and 14 were evaluated using the Illumina HiSeq 4000 platform for 324 cancer-associated genes. Patients' ages ranged from 39 to 80 (median = 59.5 years) with a male to female ratio of 1.25:1. Morphology was predominantly oncocytoma-like with discrete nests, compared to the solid and edematous patterns described in LOT. Other than positive keratin 7 and negative KIT, the tumor cells were positive for PAX8, E-cadherin, AE1/AE3, Ber-EP4, AMACR, CD10, and MOC31, and were negative for other studied markers. FH and INI1 were normal. Eleven of 14 harbored genomic abnormalities, likely sporadic, primarily involving the MTOR pathway (73%). Overall, the alterations included MTOR activating mutation (n = 1), TSC1 inactivating mutation (n = 1), TSC2 mutation (p.X534 splice site, n = 1), STK11 (a negative regulator of the MTOR pathway) mutation (n = 1), both STK11 and TSC1 mutations (n = 1), biallelic loss of PTEN and TSC1 deletion (n = 1), and MET amplification and TSC1 inactivating mutation (n = 1). Amplification of FGFR3 was identified in one additional tumor. Other alterations included FOXP1 loss (n = 1), NF2 E427 homozygous loss (n = 1), and PI3KCA activating mutation (n = 1). At a median follow-up of 68 months (2-147 months) for 15 patients, all were alive without disease. Oncocytic renal tumors with diffuse keratin 7 labeling show frequent alterations in the TSC/MTOR pathway, despite more oncocytoma-like morphology than initially described in LOT, likely expanding the morphologic spectrum of the latter.
低级别嗜酸细胞瘤(LOT)最近被提议为一种独特的肾肿瘤。然而,我们遇到了一些形态更类似于肾嗜酸细胞瘤但弥漫性角蛋白 7 阳性的肿瘤,我们试图对其进行分子特征分析。从 184 例主要为嗜酸细胞瘤样组织学的肿瘤中,我们发现了 18 例弥漫性角蛋白 7 阳性和 KIT 阴性的肿瘤。这些肿瘤接受了详细的免疫组织化学评估,其中 14 例使用 Illumina HiSeq 4000 平台对 324 个癌症相关基因进行了评估。患者年龄为 39-80 岁(中位年龄 59.5 岁),男女比例为 1.25:1。形态主要为嗜酸细胞瘤样,有离散的巢状结构,与 LOT 中描述的实性和水肿性形态不同。除了角蛋白 7 阳性和 KIT 阴性外,肿瘤细胞还表达 PAX8、E-钙黏蛋白、AE1/AE3、Ber-EP4、AMACR、CD10 和 MOC31,不表达其他研究标记物。FH 和 INI1 正常。14 例中有 11 例存在可能为散发性的基因组异常,主要涉及 MTOR 通路(73%)。总的来说,这些改变包括 MTOR 激活突变(n=1)、TSC1 失活突变(n=1)、TSC2 突变(p.X534 剪接位点,n=1)、STK11(MTOR 通路的负调节因子)突变(n=1)、STK11 和 TSC1 突变(n=1)、PTEN 双等位基因缺失和 TSC1 缺失(n=1)以及 MET 扩增和 TSC1 失活突变(n=1)。另外一个肿瘤中还发现了 FGFR3 扩增。其他改变包括 FOXP1 缺失(n=1)、NF2 E427 纯合性缺失(n=1)和 PI3KCA 激活突变(n=1)。在对 15 例患者进行的中位随访 68 个月(2-147 个月)中,所有患者均存活且无疾病进展。弥漫性角蛋白 7 染色的嗜酸细胞瘤性肾肿瘤尽管形态更类似于 LOT,但存在频繁的 TSC/MTOR 通路改变,这可能扩大了 LOT 的形态谱。